|Site||Study design||Drug and regimens|
|Kenya, Asembo (Rarieda district)||Randomized controlled trial||
SP + 3 days of artesunate (AS) 3 days of amodiaquine (AQ)+AS, 3 days of chlorproguanil-dapsone (CD), or 3 days of placebo; all arms with daily iron supplementation from 2 to 6.5 months of age|
Day 1 dose of study drugs provided at 10, and 14 weeks and 9 months EPI visit. On day 2 and 3 the drug was administered in the home under supervision by compliance monitors. Follow-up to 24 months
|North-eastern Tanzania, Korogwe and Same districts||
3 days of CD, or 3 days of placebo.
The drugs were administered at 3, 4 and 9 months, with the first dose of the drug administered under supervision at the clinic and the 2nd and 3rd dose at home unsupervised. Follow-up until 24 months.
|Gabon, Lambaréné||SP or placebo was administered at 3, 9, and 15 months, follow-up until 30 months of age.|
|Ghana (Navrongo), Bawku, Kassena-Nankana, Bolgatanga and Builsa districts||Implementation study||SP at the time of PENTA 2, PENTA 3 and measles vaccinations administered at 2 months, 3 months and 9 months respectively.|
|Malawi, Lilongwe and Salima||SP was administered at the time of DPT2 (10 weeks), DPT3 (14 weeks) and measles vaccinations (9 months).|